Gansu Longshenrongfa Pharmaceutical Industry Co Ltd (SHE:300534) — Market Cap & Net Worth
Market Cap & Net Worth: Gansu Longshenrongfa Pharmaceutical Industry Co Ltd (300534)
Gansu Longshenrongfa Pharmaceutical Industry Co Ltd (SHE:300534) has a market capitalization of $337.36 Million (CN¥2.31 Billion) as of June 17, 2026. Listed on the SHE stock exchange, this China-based company holds position #14385 globally and #4321 in its home market, demonstrating a 0.53% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Gansu Longshenrongfa Pharmaceutical Industry Co Ltd's stock price CN¥7.60 by its total outstanding shares 303345000 (303.35 Million). Review Gansu Longshenrongfa Pharmaceutical Indu (300534) financial obligations to assess the company's total debt and financial obligations.
Gansu Longshenrongfa Pharmaceutical Industry Co Ltd Market Cap History: 2016 to 2026
Gansu Longshenrongfa Pharmaceutical Industry Co Ltd's market capitalization history from 2016 to 2026. Data shows growth from $800.32 Million to $337.36 Million (3.27% CAGR).
Gansu Longshenrongfa Pharmaceutical Industry Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Gansu Longshenrongfa Pharmaceutical Industry Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.47x
Gansu Longshenrongfa Pharmaceutical Industry Co Ltd's market cap is 0.47 times its annual revenue
Latest Price to Earnings (P/E) Ratio
9.57x
Gansu Longshenrongfa Pharmaceutical Industry Co Ltd's market cap is 9.57 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $800.32 Million | $269.68 Million | $47.25 Million | 2.97x | 16.94x |
| 2017 | $440.00 Million | $269.59 Million | $17.11 Million | 1.63x | 25.71x |
| 2018 | $251.73 Million | $203.17 Million | $12.28 Million | 1.24x | 20.50x |
| 2019 | $262.25 Million | $239.00 Million | $12.78 Million | 1.10x | 20.52x |
| 2020 | $255.64 Million | $254.90 Million | $1.83 Million | 1.00x | 139.61x |
| 2021 | $649.92 Million | $287.81 Million | -$9.11 Million | 2.26x | N/A |
| 2022 | $391.63 Million | $799.68 Million | $38.79 Million | 0.49x | 10.10x |
| 2023 | $435.78 Million | $1.08 Billion | $61.65 Million | 0.40x | 7.07x |
| 2024 | $386.18 Million | $1.04 Billion | $25.80 Million | 0.37x | 14.97x |
| 2025 | $420.81 Million | $886.96 Million | $43.95 Million | 0.47x | 9.57x |
Competitor Companies of 300534 by Market Capitalization
Companies near Gansu Longshenrongfa Pharmaceutical Industry Co Ltd in the global market cap rankings as of June 17, 2026.
Key companies related to Gansu Longshenrongfa Pharmaceutical Industry Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #513 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #561 globally with a market cap of $48.78 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #624 globally with a market cap of $44.20 Billion USD ( CN¥302.05 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #635 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #513 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #561 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $43.22 |
| #624 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $44.20 Billion | CN¥47.35 |
| #635 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €13.60 |
Gansu Longshenrongfa Pharmaceutical Industry Co Ltd Historical Marketcap From 2016 to 2026
Between 2016 and today, Gansu Longshenrongfa Pharmaceutical Industry Co Ltd's market cap moved from $800.32 Million to $ 337.36 Million, with a yearly change of 3.27%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥337.36 Million | -19.83% |
| 2025 | CN¥420.81 Million | +8.97% |
| 2024 | CN¥386.18 Million | -11.38% |
| 2023 | CN¥435.78 Million | +11.27% |
| 2022 | CN¥391.63 Million | -39.74% |
| 2021 | CN¥649.92 Million | +154.23% |
| 2020 | CN¥255.64 Million | -2.52% |
| 2019 | CN¥262.25 Million | +4.18% |
| 2018 | CN¥251.73 Million | -42.79% |
| 2017 | CN¥440.00 Million | -45.02% |
| 2016 | CN¥800.32 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 17th, 2026 the market cap of Gansu Longshenrongfa Pharmaceutical Industry Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $337.36 Million USD |
| MoneyControl | $337.36 Million USD |
| MarketWatch | $337.36 Million USD |
| marketcap.company | $337.36 Million USD |
| Reuters | $337.36 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Gansu Longshenrongfa Pharmaceutical Industry Co Ltd
Gansu Longshenrongfa Pharmaceutical Industry CO.,LTD researches, develops, produces, and sells traditional Chinese medicines, medical devices, and health products in China and internationally. It is also involved in the cultivation, processing, and sales of chemical drugs and medicinal herbs, as well as pharmaceutical distribution, testing, and inspection services. The company was founded in 2002… Read more